Cybin (HELP) Receivables (2021 - 2026)
Cybin's (HELP) quarterly Receivables came in at $5.0 million in Q1 2026, up 22.59% YoY from $4.1 million in Q1 2025, and up 5.5% on a QoQ basis from $4.8 million in Q4 2025.
Cybin (HELP) Receivables (2021 - 2026) Analysis & Trends
Cybin (HELP) has 6 years of Receivables data on file, last reported at $5.0 million in Q1 2026.
- Quarterly Receivables rose 22.59% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 22.59% YoY) and the FY2026 annual result came in at $5.0 million, up 22.81% from the prior year.
- Receivables advanced to $5.0 million in Q1 2026, from $4.8 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $5.0 million in Q1 2026 to a low of $900271.9 in Q1 2023.
- A 5-year average of $3.4 million and a median of $3.4 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables rose 11.29% — and 2023, when it jumped 63.4%.
- Tracing HELP's Receivables over 5 years: stood at $1.9 million in 2022, then jumped by 63.4% to $3.1 million in 2023, then grew by 27.84% to $4.0 million in 2024, then advanced by 19.25% to $4.8 million in 2025, then increased by 5.5% to $5.0 million in 2026.
- The last three Receivables figures came in at $5.0 million (Q1 2026), $4.8 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | 5.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.03 Mn |
| Dec 31, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.04 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.32 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 2.75 Mn |
| Jun 30, 2023 | 2.86 Mn |
| Feb 28, 2023 | 900,271.88 |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 1.81 Mn |
| Jun 30, 2021 | 1.36 Mn |
| Mar 31, 2021 | 1.05 Mn |